Company / Operating Cash Flow
KalVista Pharmaceuticals, Inc. Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$152.9M
FY2025
5-year range
-$152.9M / -$75.3M
FY2021-FY2025
Trend
+0.0%
vs FY2024
Sector context
#152 of 216
Health Care
What the data says
At -$153M, KalVista Pharmaceuticals, Inc.'s operating cash flow ranks #152 of 216 in the Health Care sector. Operating Cash Flow has fluctuated over the past 10 years, ranging from -$153M in FY2025 to $11M in FY2017.
Based on SEC 10-K filings.
-$153M in FY2025.
Declined from -$89M to -$153M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#152 of 216 in Health CareTop 70% of 216This company -$152.9M Sector average $659.0M
▼
-123.2% below sector average
Key checks
Key Insights
- In FY2025, operating cash flow increased 0.0% year-over-year.
- Ranks #152 out of 216 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2017.
Company context
Key Data Points
- Altman Z-Score -3.72 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$152.9M | +0.0% |
| FY2024 | -$152.9M | -71.4% |
| FY2023 | -$89.2M | -18.6% |
| FY2022 | -$75.3M | +3.7% |
| FY2021 | -$78.1M | -159.0% |
| FY2020 | -$30.2M | -27.2% |
| FY2019 | -$23.7M | -80.3% |
| FY2018 | -$13.2M | -224.6% |
| FY2017 | $10.6M | +144.5% |
| FY2016 | -$23.7M | -80.3% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026